Phase Holographic Imaging Announces Next Generation HoloMonitor
Phase Holographic Imaging (PHI) is pleased to announce that the next generation of PHI’s live cell imaging system enters its final development stage. The new model is currently undergoing pre-production testing both internally and externally at the Huntsman Cancer Institute and Wake Forest Institute of Regenerative Medicine.
The HoloMonitor CellSync marks the first in a series of models, with the long-term goal of delivering a clinical-grade product designed to set a new standard for automated quality control in cell and gene therapy manufacturing. The series is expected to include the latest developments in image processing and artificial intelligence.
Manufactured by our production partner in accordance with ISO 9001 standards, the HoloMonitor CellSync builds on the success of its predecessor, offering non-invasive, real-time imaging of live cells. It incorporates the latest advancements in PHI’s core imaging technology, including an updated camera module and enhanced automated cell segmentation, which has been developed over the past two years.
“We’re excited to take this next step in advancing our technology,” says Ivan Jurković, CEO of Phase Holographic Imaging. “Having met our targets for the first half of 2025, we are well on track to finalize the first clinically applicable version of HoloMonitor.”
HoloMonitor CellSync is expected to launch in the second half of 2025.
For additional information, please contact:
Ivan Jurkovic
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
Subscribe to PHI news on cision.com
